[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].

Coman T, Andreozzi F, Bay JO, Cornillon J, Guillaume T, Hamzy F, Souchet L, Turlure P, Marçais A, Dachy F, Beguin Y, Bulabois CE, Daghri S, Huynh A, Magro L, Chalandon Y